78 studies found for:    "Kennedy disease"
Show Display Options
Rank Status Study
21 Recruiting A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
Condition: Prostate Cancer
Interventions: Biological: pTVG-AR;   Biological: gm-csf
22 Recruiting Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Condition: Triple Negative Breast Cancer
Intervention: Drug: GTx-024
23 Suspended Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Biomarker Analysis;   Drug: Enzalutamide;   Other: Pharmacological Study;   Drug: Taselisib
24 Recruiting Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC)
Condition: Breast Cancer
Interventions: Drug: Enzalutamide;   Drug: Paclitaxel
25 Recruiting Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling
Condition: Prostate Cancer
Intervention: Drug: Enzalutamide
26 Not yet recruiting A Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castrate-resistant Prostate Cancer Patients
Conditions: Metastatic Castrate-resistant Prostate Cancer;   Adenocarcinoma, Prostate
Intervention: Drug: TRC253
27 Withdrawn Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery
Condition: Breast Cancer Female
Interventions: Drug: oral microencapsulated diindolylmethane;   Other: laboratory biomarker analysis
28 Terminated A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
Condition: Prostate Cancer
Interventions: Drug: Galeterone;   Drug: Enzalutamide
29 Completed Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia
Condition: Androgenetic Alopecia
Intervention: Drug: Finasteride
30 Terminated Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients
Condition: Breast Cancer
Intervention: Drug: Bicalutamide
31 Active, not recruiting Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy
Condition: Prostate Cancer
Intervention: Procedure: Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging
32 Recruiting Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
Condition: Salivary Gland Cancer
Interventions: Drug: bicalutamide + triptorelin;   Drug: Cisplatin + Doxorubicin;   Drug: Carboplatin + Paclitaxel
33 Recruiting A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
Conditions: Advanced Breast Cancer;   Human Epidermal Growth Factor Receptor 2 (HER2);   HER2 Amplified
Interventions: Drug: enzalutamide;   Drug: trastuzumab
34 Completed Effect of Functional Exercise in Patients With Spinal Bulbar Muscular Atrophy
Condition: Motor Neuron Disease
Interventions: Behavioral: A functional exercise program;   Behavioral: A stretching exercise program
35 Recruiting CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer
Conditions: Metastatic Breast Adenocarcinoma;   Breast Cancer
Intervention: Drug: CR1447
36 Active, not recruiting A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostatic Neoplasms, Castration-Resistant
Intervention: Drug: JNJ-56021927
37 Suspended A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
Condition: Prostatic Neoplasm
Intervention: Drug: EZN-4176
38 Not yet recruiting Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients With Localized Prostate Cancer Before Surgery
Conditions: Stage III Prostate Adenocarcinoma;   Stage III Prostate Cancer;   Stage IV Prostate Adenocarcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Abiraterone Acetate;   Drug: Androgen Receptor Antagonist ARN-509;   Drug: Degarelix;   Drug: Indomethacin;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone
39 Not yet recruiting Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
Conditions: Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
Interventions: Drug: Abiraterone Acetate;   Drug: Androgen Receptor Antagonist ARN-509;   Biological: Gonadotropin-releasing Hormone Analog;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Procedure: Radical Prostatectomy
40 Recruiting CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)
Conditions: Cancer of the Breast;   Breast Cancer;   Advanced Breast Cancer;   Metastatic Breast Cancer;   Male Breast Cancer;   Triple Negative Breast Cancer;   ER+ Breast Cancer
Interventions: Drug: Female AR(+) TNBC Enzalutamide Naïve;   Drug: Female AR(+) TNBC Enzalutamide Treated;   Drug: Female ER(+) BC Patients;   Drug: Male ER(+) BC Patients

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.